HK Stock MarketDetailed Quotes

02563 BIOSTAR PHARM-B

Watchlist
  • 28.300
  • -0.550-1.91%
Trading Nov 28 10:12 CST
10.32BMarket Cap-57287P/E (TTM)

BIOSTAR PHARM-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
Cash flow from operating activities
Earning before tax
-18.15%-189.64M
-64.47%-130.19M
---160.51M
---79.16M
Profit adjustment
Interest (income) - adjustment
-310.39%-11.69M
-687.79%-10.32M
---2.85M
---1.31M
Investment loss (gain)
16.14%-9.1M
33.33%-8.52M
---10.85M
---12.78M
Impairment and provisions:
-142.20%-511K
-183.23%-561K
--1.21M
--674K
-Impairmen of inventory (reversal)
--773K
--718K
----
----
-Impairment of trade receivables (reversal)
-206.03%-1.28M
-289.76%-1.28M
--1.21M
--674K
Depreciation and amortization:
1.14%10.62M
3.30%8.05M
--10.5M
--7.79M
-Amortization of intangible assets
2.47%1.21M
3.31%904K
--1.18M
--875K
Financial expense
-19.72%57K
-2.08%47K
--71K
--48K
Exchange Loss (gain)
76.27%-4.65M
72.77%-6.56M
---19.6M
---24.11M
Special items
-45.00%44.4M
-34.99%36.33M
--80.74M
--55.88M
Operating profit before the change of operating capital
-58.47%-160.51M
-110.96%-111.74M
---101.29M
---52.97M
Change of operating capital
Inventory (increase) decrease
136.35%3.07M
154.97%3.56M
---8.44M
---6.47M
Accounts receivable (increase)decrease
465.42%25.22M
247.47%19.62M
---6.9M
---13.3M
Accounts payable increase (decrease)
-88.01%3.39M
-132.80%-3.76M
--28.23M
--11.47M
prepayments (increase)decrease
-2,532.94%-8.95M
-7.05%-6.91M
---340K
---6.46M
Cash  from business operations
-55.27%-137.79M
-46.51%-99.23M
---88.74M
---67.73M
Special items of business
-224.06%-11.54M
-223.65%-11.46M
--9.3M
--9.27M
Net cash from operations
-87.99%-149.33M
-89.34%-110.69M
---79.44M
---58.46M
Cash flow from investment activities
Decrease in deposits (increase)
71.97%-60.81M
67.78%-64.85M
---216.92M
---201.29M
Purchase of fixed assets
12.62%-27.84M
-26.26%-25.33M
---31.86M
---20.06M
Purchase of intangible assets
----
----
---817K
---757K
Recovery of cash from investments
-8.09%753.48M
-2.66%499.64M
--819.81M
--513.32M
Cash on investment
25.38%-535M
39.26%-280M
---717M
---461M
Net cash from investment operations
188.45%129.83M
176.24%129.46M
---146.79M
---169.8M
Net cash before financing
91.38%-19.5M
108.22%18.76M
---226.23M
---228.26M
Cash flow from financing activities
New borrowing
----
----
--70K
--70K
Refund
---68K
---68K
----
----
Interest paid - financing
19.72%-57K
2.08%-47K
---71K
---48K
Other items of the financing business
-128.44%-1.01M
-121.56%-849K
--3.53M
--3.94M
Net cash from financing operations
-131.98%-1.13M
-124.35%-964K
--3.53M
--3.96M
Effect of rate
-109.64%-1.39M
-93.03%865K
--14.38M
--12.41M
Net Cash
90.73%-20.63M
107.94%17.8M
---222.69M
---224.3M
Begining period cash
-77.61%60.11M
-77.61%60.11M
--268.42M
--268.42M
Cash at the end
-36.63%38.09M
39.37%78.77M
--60.11M
--56.52M
Cash balance analysis
Currency Unit
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
HKAS
HKAS
HKAS
Audit Opinions
Unqualified Opinion
--
Unqualified Opinion
--
Auditor
KPMG
--
KPMG
--
(FY)Dec 31, 2023(Q9)Sep 30, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022
Cash flow from operating activities
Earning before tax -18.15%-189.64M-64.47%-130.19M---160.51M---79.16M
Profit adjustment
Interest (income) - adjustment -310.39%-11.69M-687.79%-10.32M---2.85M---1.31M
Investment loss (gain) 16.14%-9.1M33.33%-8.52M---10.85M---12.78M
Impairment and provisions: -142.20%-511K-183.23%-561K--1.21M--674K
-Impairmen of inventory (reversal) --773K--718K--------
-Impairment of trade receivables (reversal) -206.03%-1.28M-289.76%-1.28M--1.21M--674K
Depreciation and amortization: 1.14%10.62M3.30%8.05M--10.5M--7.79M
-Amortization of intangible assets 2.47%1.21M3.31%904K--1.18M--875K
Financial expense -19.72%57K-2.08%47K--71K--48K
Exchange Loss (gain) 76.27%-4.65M72.77%-6.56M---19.6M---24.11M
Special items -45.00%44.4M-34.99%36.33M--80.74M--55.88M
Operating profit before the change of operating capital -58.47%-160.51M-110.96%-111.74M---101.29M---52.97M
Change of operating capital
Inventory (increase) decrease 136.35%3.07M154.97%3.56M---8.44M---6.47M
Accounts receivable (increase)decrease 465.42%25.22M247.47%19.62M---6.9M---13.3M
Accounts payable increase (decrease) -88.01%3.39M-132.80%-3.76M--28.23M--11.47M
prepayments (increase)decrease -2,532.94%-8.95M-7.05%-6.91M---340K---6.46M
Cash  from business operations -55.27%-137.79M-46.51%-99.23M---88.74M---67.73M
Special items of business -224.06%-11.54M-223.65%-11.46M--9.3M--9.27M
Net cash from operations -87.99%-149.33M-89.34%-110.69M---79.44M---58.46M
Cash flow from investment activities
Decrease in deposits (increase) 71.97%-60.81M67.78%-64.85M---216.92M---201.29M
Purchase of fixed assets 12.62%-27.84M-26.26%-25.33M---31.86M---20.06M
Purchase of intangible assets -----------817K---757K
Recovery of cash from investments -8.09%753.48M-2.66%499.64M--819.81M--513.32M
Cash on investment 25.38%-535M39.26%-280M---717M---461M
Net cash from investment operations 188.45%129.83M176.24%129.46M---146.79M---169.8M
Net cash before financing 91.38%-19.5M108.22%18.76M---226.23M---228.26M
Cash flow from financing activities
New borrowing ----------70K--70K
Refund ---68K---68K--------
Interest paid - financing 19.72%-57K2.08%-47K---71K---48K
Other items of the financing business -128.44%-1.01M-121.56%-849K--3.53M--3.94M
Net cash from financing operations -131.98%-1.13M-124.35%-964K--3.53M--3.96M
Effect of rate -109.64%-1.39M-93.03%865K--14.38M--12.41M
Net Cash 90.73%-20.63M107.94%17.8M---222.69M---224.3M
Begining period cash -77.61%60.11M-77.61%60.11M--268.42M--268.42M
Cash at the end -36.63%38.09M39.37%78.77M--60.11M--56.52M
Cash balance analysis
Currency Unit CNYCNYCNYCNY
Accounting Standards HKASHKASHKASHKAS
Audit Opinions Unqualified Opinion--Unqualified Opinion--
Auditor KPMG--KPMG--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data